News
Expansion of the peptide hormone antibody portfolio
August 23 2010
Product launch: Pig NGAL ELISA Kit (KIT 044)
August 12 2010
AACC/Clinical Lab Expo 2010, July 27-29, Anaheim, CA
July 06 2010
IUTOX 2010, July 19-23, Barcelona, Spain
June 30 2010
BioPorto Diagnostics at the ERA-EDTA Congress, Munich, June 25-28
June 14 2010
BioPorto Diagnostics at APCN 2010, June 5-8, Seoul, Korea
May 21 2010
Presentation of The NGAL Test data at the BRS/RA Conference, May 17-20, Manchester, UK
May 14 2010
Product launch: new monoclonal antibodies available
May 07 2010
Presentation of The NGAL Test data at the 30th International Symposium on Intensive Care and Emergency Medicine (ISICEM)
February 22 2010
BioPorto Diagnostics obtains Quality Management Certification
February 18 2010
BioPorto Diagnostics at the Biomarker World Congress 2009, May 27-29, Philadelphia
May 26 2009 by Ana Belén Enfedaque Buisán
Since the very identification of NGAL as an early marker for kidney injury, BioPorto Diagnostics has offered NGAL assays and antibodies. The value of NGAL as an acute kidney injury marker in humans has gained strong support through widely published scientific literature. Furthermore, NGAL has also proven to be invaluable to the pharmaceutical industry in its use as a marker of nephrotoxicity in experimental animals.
The Biomarker World Congress 2009 addresses both of these market segments for NGAL by spanning the pharmaceutical and diagnostic pipeline in a unique and international mix of large and medium pharmaceutical, biotech and diagnostics companies, leading universities and clinical research institutions, amongst others. The perfect meeting-place to share experience, foster collaborations across industry and academia, and evaluate emerging technologies.
Jakob Ohm Eriksen, NGAL pharma (clinical and preclinical) Product Manager will attend the congress on behalf of BioPorto Diagnostics. Contact him at joe@bioporto.com.
For further information on the event: http://www.biomarkerworldcongress.com/
